MEMBRANEBLUE

Manufacturer
Dutch Ophthalmic Research Center (International) B.V. | Pharmpur GmbH
Effective date
2025-11-24
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
17
Source
full-release
Hydrated at
2026-05-31 21:47:02

Label at a glance#

ProductMEMBRANEBLUE
Active ingredientTRYPAN BLUE
Label structure14 sections

Storage and handling

Storage: Store between 15ºC to 25ºC (59ºF to 77ºF). Protect from direct sunlight. Single-patient-use. Discard unused portion.

Label contents#

Full prescribing information#

MembraneBlue 0.15% - Indications & Usage Section

INDICATIONS & USAGE SECTION

MembraneBlue™ 0.15% is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue in adults and pediatric patients.

MembraneBlue 0.15% - Dosage & administration section

DOSAGE & ADMINISTRATION SECTION

MembraneBlue 0.15% is packaged in a single-patient-use syringe filled to a volume of 0.5 mL. Make sure the plunger moves smoothly before use. Prime the syringe prior to use by retracting the plunger before injecting the fluid. Alternatively, twist the plunger into the stopper in a clockwise motion until tight. Once tight, continue turning the plunger in a clockwise motion until the stopper rotates freely within the syringe, two or three rotations. The syringe is now primed and suitable for injection.

Before injection of MembraneBlue perform a “fluid-air exchange” (i.e., filling the entire vitreous cavity with air, to prevent aqueous dilution of MembraneBlue). MembraneBlue is carefully applied to the retinal membrane using a blunt cannula attached to the MembraneBlue syringe, without allowing the cannula to contact or damage the retina. Sufficient staining is expected on contact with the membrane. All excess dye should be removed from the vitreous cavity before performing an air-fluid exchange, to prevent unnecessary spreading of the dye.

MembraneBlue can also be injected directly in a BSS filled vitreous cavity (instead of injecting under air). Clinical use demonstrated that, after complete vitreous and posterior hyaloid removal, sufficient staining is achieved after 30 seconds of application under BSS.

MembraneBlue is intended to be applied directly on the areas where membranes could be present, staining any portion of the membrane which comes in contact with the dye. The dye does not penetrate the membrane.

MembraneBlue 0.15% - Dosage forms & strengths section.

DOSAGE FORMS & STRENGTHS SECTION

MembraneBlue (trypan blue ophthalmic solution) 0.15% is a clear, dark blue ophthalmic solution supplied in a 2.25 mL single-patient-use syringe filled to a volume of 0.5 mL.

MembraneBlue 0.15% - Contraindications section.

CONTRAINDICATIONS SECTION

MembraneBlue 0.15% is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye. The dye may be absorbed by the IOL and stain it.

MembraneBlue 0.15% - Warnings and precautions section

WARNINGS AND PRECAUTIONS SECTION

Excessive Staining

Excess MembraneBlue 0.15% should be immediately removed from the eye after staining.

Priming of the Syringe

To make sure the plunger moves smoothly before use, first retract the plunger or twist the plunger in a clockwise motion before injecting the fluid.

MembraneBlue 0.15% - Adverse reactions section

ADVERSE REACTIONS SECTION

Adverse reactions reported following use of MembraneBlue 0.15% include discoloration of high water content hydrogen intraocular lenses [see Contraindications] and inadvertent staining of the posterior lens capsule and vitreous face. Staining of the posterior lens capsule or staining of the vitreous face is generally self limited, lasting up to one week.

MembraneBlue - Use in specific populations section

USE IN SPECIFIC POPULATIONS SECTION

MembraneBlue - Pregnancy section

PREGNANCY SECTION

Risk Summary
There are no available data on the use of MembraneBlue 0.15% in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Systemic absorption of MembraneBlue 0.15% in humans is expected to be negligible following injection and subsequent removal of the drug at the completion of surgical procedures. Adequate animal reproduction studies were not conducted with MembraneBlue 0.15%, however, trypan blue has been shown to be teratogenic in various animal models at doses 323-fold and greater than the maximum recommended human dose, based on body surface area (BSA).

Due to the negligible human systemic exposure when used as recommended, it is not expected that maternal use of MembraneBlue will result in fetal exposure to the drug and risk of teratogenic effects.

Data

Animal Data

Trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. The majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. The teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. Normalized to BSA, these doses are approximately 645- and 323-fold the maximum recommended human dose of 0.75 mg per injection (based on a 60 kg person), assuming complete systemic absorption of trypan blue. Characteristic anomalies included neural tube, cardiovascular, vertebral, tail, and eye defects. Trypan blue also caused an increase in post-implantation mortality and decreased fetal weight. In the monkey, trypan blue caused abortions with single or two daily doses of 50 mg/kg between 20th to 25th days of pregnancy, but no apparent increase in birth defects (approximately 1,300-fold the maximum recommended human dose based on BSA, assuming complete systemic absorption).

MembraneBlue - Lactation section

NURSING MOTHERS SECTION

Risk Summary


The presence of trypan blue in human milk following intraocular administration of trypan blue has not been evaluated. There are no data available regarding the effects of trypan blue on milk production. Breastfeeding is not expected to result in exposure of the child to trypan blue due to
the negligible systemic exposure of trypan blue in humans following injection and subsequent removal of the drug at the completion of surgical procedures.

MembraneBlue - Pediatric use section

PEDIATRIC USE SECTION

The safety and effectiveness of trypan blue have been established in pediatric patients. Use of trypan blue is supported by evidence from an adequate and well-controlled study in pediatric patients.

MembraneBlue - Geriatric use

GERIATRIC USE SECTION

No overall differences in safety and effectiveness were observed between elderly and younger patients.

MembraneBlue - Description.

DESCRIPTION SECTION

MembraneBlue™ (trypan blue ophthalmic solution) 0.15% is a sterile solution of trypan blue (an acid di-azo group dye) for intraocular ophthalmic use. MembraneBlue selectively stains epiretinal membranes during ophthalmic surgical vitrectomy procedures.

Each mL of MembraneBlue 0.15% contains: 1.5 mg trypan blue; 1.9 mg sodium mono-hydrogen orthophosphate (Na 2HPO 4•2H 2O); 0.3 mg sodium di-hydrogen orthophosphate (NaH 2PO 4•2H 2O); 8.2 mg sodium chloride (NaCl); and water for injection. The pH is 7.3 - 7.6. The osmolality is 257 - 314 mOsm/kg.

The drug substance trypan blue has the chemical name 3,3'-[(3,3'-dimethyl-4,4'-biphenylylene) bis (azo)] bis (5-amino-4-hydroxy-2,7-naphthalenedisulfonic acid) tetra sodium salt, a molecular weight of 960.8, a molecular formula of C 34H 24N 6Na 4O 14S 4, and has the following chemical structure: Chemical structure MembraneBlueChemical structure MembraneBlue

MembraneBlue - Clinical Pharmacology Section

CLINICAL PHARMACOLOGY SECTION

MembraneBlue 0.15% - Mechanism of action section.

MECHANISM OF ACTION SECTION

MembraneBlue 0.15% selectively stains membranes in the human eye during posterior surgery, such as epiretinal membranes (ERM) and Internal Limiting Membranes (ILM).

MembraneBlue - Nonclinical toxicology section

NONCLINICAL TOXICOLOGY SECTION

Carinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Trypan blue is carcinogenic in rats. Wister/Lewis rats developed lymphomas after receiving subcutaneous injections of 1% trypan blue dosed at 50 mg/kg every other week for 52 weeks (approximately 645-fold the maximum recommended human dose of 0.75 mg per injection in a 60 kg person based on BSA, assuming complete systemic absorption).

Mutagenesis
Trypan blue was mutagenic in the Ames test and caused DNA strand breaks in vitro.

MembraneBlue - How supplied section

HOW SUPPLIED SECTION

MembraneBlue (trypan blue ophthalmic solution) 0.15% is a clear, dark blue ophthalmic solution supplied as follows:

0.5 mL of MembraneBlue 0.15% in a sterile single-patient-use Luer Lock, 2.25 mL glass syringe, grey rubber plunger stopper and tip cap with polypropylene plunger rod in a peel pouch. Five pouched products are packed in one distribution box.

NDC 68803-672-01 (One 0.5 mL syringe)
NDC 68803-672-05 (Carton of five 0.5 mL syringes)

MembraneBlue - Storage and handling section

STORAGE AND HANDLING SECTION

Storage: Store between 15ºC to 25ºC (59ºF to 77ºF). Protect from direct sunlight. Single-patient-use. Discard unused portion.

SPL UNCLASSIFIED SECTION

Made in Germany

Distributed in the United States by

Dutch Ophthalmic, USA

10, Continental Drive, Bldg 1

Exeter, NH 03833, USA

Phone: 800-75-DUTCH or 603-778-6929

MembraneBlue 0.15% - Package label.Principal display panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

MembraneBlue - BoxMembraneBlue - Box

MembraneBlue - labellingMembraneBlue - labelling

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TRYPAN BLUE FREE ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeCode 12800000Scan labeling 20131220.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
3c386306-c48a-413e-bb69-70cb268496f3Product name120210727
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
68803-672-052025-11-24C16284748780-19d75b9d0-994c-f424-e053-dadaa90a57ceMembraneBlue™ 0.15% (trypan blue ophthalmic solution). These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%. MembraneBlue™ 0.15% (trypan blue ophthalmic solution) Initial U.S. Approval: 2004
68803-672-052023-01-30C16284748780-19d75b9d0-994c-f424-e053-dadaa90a57ceMembraneBlue™ 0.15% (trypan blue ophthalmic solution). These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%. MembraneBlue™ 0.15% (trypan blue ophthalmic solution) Initial U.S. Approval: 2004
68803-672-052020-10-08C16284748780-19d75b9d0-994c-f424-e053-dadaa90a57ceMembraneBlue™ 0.15% (trypan blue ophthalmic solution). These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%. MembraneBlue™ 0.15% (trypan blue ophthalmic solution) Initial U.S. Approval: 2004
68803-672-052020-01-31C16284748780-19d75b9d0-994c-f424-e053-dadaa90a57ceMembraneBlue™ 0.15% (trypan blue ophthalmic solution). These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%. MembraneBlue™ 0.15% (trypan blue ophthalmic solution) Initial U.S. Approval: 2004

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68803-672-05MEMBRANEBLUE1 in 1 POUCHINJECTION, SOLUTION117
68803-672-05MEMBRANEBLUE5 in 1 CARTONINJECTION, SOLUTION517

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
68803-672-05ML - Milliliter68803-67298e1aaca-d63e-4a4a-bb64-a24de33bec8c12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
TRYPAN BLUEACTIVE INGREDIENTI2ZWO3LS3M5
TRYPAN BLUEACTIVE MOIETYI2ZWO3LS3M5
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X5
SODIUM PHOSPHATE, DIBASIC, DIHYDRATEINACTIVE INGREDIENT94255I6E2T5
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEINACTIVE INGREDIENT5QWK6659565
WATERINACTIVE INGREDIENT059QF0KO0R5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68803-67268803-672-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 92 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956SOLUTION / OPHTHALMIC2 mgExact identifier — unii+route
16 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / INTRAVENOUS55 mgExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INFILTRATION3535 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / INTRATHECAL0.01 %w/vExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRA-ARTERIAL278 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRA-ARTERIAL278 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / OPHTHALMIC13 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TSOLUTION/ DROPS / OPHTHALMIC1.2 %w/vExact identifier — unii+route
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRACAUDAL210 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / INTRAVENOUS115 mgExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBMUCOSAL16 %w/vExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INFILTRATION3535 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVESICAL351 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVESICAL351 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / INTRAVENOUS55 mgExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / OPHTHALMIC10 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / EPIDURAL3535 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBMUCOSAL16 %w/vExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, FOR SOLUTION / OPHTHALMIC0.9 %w/wExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / SUBCUTANEOUS0.14 %w/vExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / OPHTHALMIC55 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / SUBCUTANEOUS0.3 %w/vExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, FOR SOLUTION / OPHTHALMIC0.9 %w/wExact identifier — unii+route
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRACAUDAL210 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / OPHTHALMIC10 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XDROPS / OPHTHALMIC0.08 %w/wExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / INTRAVENOUS55 mgExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION/ DROPS / OPHTHALMIC3 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / SUBCUTANEOUS0.14 %w/vExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / OPHTHALMIC13 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / INTRAVENOUS55 mgExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR0.86 %w/vExact identifier — unii+route
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVENOUS2916 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / SUBCUTANEOUS0.3 %w/vExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / PARENTERAL210 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBARACHNOID0.9 %w/vExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / SUBCUTANEOUS0.3 %w/vExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / INTRAVENOUS115 mgExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INFILTRATION3535 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XDROPS / OPHTHALMIC0.08 %w/wExact identifier — unii+route
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVESICAL351 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVENOUS2916 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAOCULAR320 mgExact identifier — unii+route
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / PARENTERAL210 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR0.86 %w/vExact identifier — unii+route
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / INTRATHECAL0.01 %w/vExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / INTRAVENOUS115 mgExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVENOUS2916 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBARACHNOID0.9 %w/vExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / SUBCUTANEOUS0.14 %w/vExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / EPIDURAL3535 mgExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBMUCOSAL16 %w/vExact identifier — unii+dosage form
66 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASIC, DIHYDRATESODIUM PHOSPHATE, DIBASIC, DIHYDRATE94255I6E2TINJECTION, SOLUTION / SUBCUTANEOUS0.14 %w/vExact identifier — unii+dosage form
10 equally ranked IID candidates
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATESODIUM PHOSPHATE, MONOBASIC, DIHYDRATE5QWK665956INJECTION, SOLUTION / INTRATHECAL0.01 %w/vExact identifier — unii+dosage form
16 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVESICAL351 mgExact identifier — unii+dosage form
66 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N022278-001MEMBRANEBLUETRYPAN BLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-2084e616aacf4f…
2026-08-18 06:07:402026-07N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-2031067a03dcf5…
2025-08-23 18:47 UTC2025-08N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-206a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-2003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-202680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-205bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-2079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-201e350fbaab3a…
2024-05-31 18:47 UTC2024-05N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-208072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-205c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-205d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-204b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-2074a2ff9319b5…
2022-03-09 01:35 UTC2022-03N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-20bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-20782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-2087673890dc5c…
2021-03-12 10:30 UTC2021-03N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-205aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-208869cabd3fbd…
2020-11-12 02:37 UTC2020-11N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-20c0c555d07b60…
2019-12-14 00:12 UTC2019-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-203f01610625f2…
2019-09-15 20:21 UTC2019-09N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-20b00525d2431f…
2019-07-19 19:46 UTC2019-07N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD, RS2009-02-20ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-206a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-201c564ffb4f44…
2023-12-20 04:57 UTC2023-12N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-209b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-203f0d92c62455…
2023-05-13 08:27 UTC2023-05N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20053a50430f4f…
2023-01-26 05:58 UTC2023-01N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-203bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-203a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N022278-001MEMBRANEBLUE0.15%SOLUTION / OPHTHALMICRLD2009-02-20f41ea6bd6efb…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2019-12-13 00:20 UTC2019-12N022278-00166964302019-05-07U-23772018-09-0674a2ff9319b5…
2019-12-13 00:20 UTC2019-12N022278-00163724492019-11-12U-23792018-09-0674a2ff9319b5…
2019-12-14 00:12 UTC2019-12N022278-00166964302019-05-07U-23772018-09-063f01610625f2…
2019-12-14 00:12 UTC2019-12N022278-00163724492019-11-12U-23792018-09-063f01610625f2…
2019-09-15 20:21 UTC2019-09N022278-00166964302019-05-07U-23772018-09-06b00525d2431f…
2019-09-15 20:21 UTC2019-09N022278-00163724492019-11-12U-23792018-09-06b00525d2431f…
2019-07-19 19:46 UTC2019-07N022278-00166964302019-05-07U-23772018-09-06ea99ee380514…
2019-07-19 19:46 UTC2019-07N022278-00163724492019-11-12U-23792018-09-06ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MEMBRANEBLUETRYPAN BLUEDutch Ophthalmic Research Center (International) B.V.0364aceb-dd3f-4bac-b468-25379a07ccfc2025-11-24Warnings, Adverse reactionsExact identifier
ndc (package): 68803-672-05
ndc (product): 68803-672
ndc11 (package): 68803067205
spl id: 44559f09-e0e2-a332-e063-6394a90aa296
spl set id: 0364aceb-dd3f-4bac-b468-25379a07ccfc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.